TFAP2A and sarcoma: TFAP2A expression is significantly higher in most cancer types except ACC, PRAD, Sarcoma (SARC), Testicular germ cell tumors (TGCT), and THCA, which is consistent with the analysis from the TIMER2 database and those in previous studies, such as in CHOL, Esophageal cancer (EC), Gastric cancer (GC), HNSC, Non-small cell lung cancers (NSCLC), OC, etc. [32, 37–41], suggests TFAP2A indeed promote oncogenesis and tumor progression.